Precision medicine and companion diagnostics for oncologists – testing, reporting and actionability


14 Dec 2021

Molecular profiling of tumours to identify targetable alterations is rapidly developing and is now part of clinical practice for a range of cancers. Genomic testing needs a co-ordinated approach to specimen collection, testing and reporting, and it’s important to be aware of the types of genomic variants reported by the laboratory and the technology used to determine the results. Limitations to current testing are also important to consider.

In this episode Professor David Thomas, CEO of Omico: Australian Genomic Cancer Medicine Centre, discusses the current status of testing, reporting and actionability in precision oncology here in Australia with Professor Linda Mileshkin and Professor Stephen Fox.

Professor Linda Mileshkin is Deputy Director of Medical Oncology and Peter MacCallum Cancer Centre. She also runs Australia’s only specialist clinic dedicated to people with Cancer of Unknown Primary. Professor Stephen Fox is Director of Pathology and Head of Molecular Pathology Laboratory, Peter Mac and Professorial Fellow, Sir Peter MacCallum Department of Oncology, University of Melbourne.

Please answer our precision medicine survey once you have listened to this podcast by clicking here.

This is the second podcast in a series of podcasts focused on Precision Oncology. In future episodes you will hear Professor Thomas in conversation with other oncologists and pathologists at the cutting edge of developments in precision oncology and personalised medicine. To listen to the first podcast please click the link below.


This podcast series has been developed independently by the limbic in collaboration with the participants. Thanks you to Roche Diagnostics Australia for providing the non restrictive educational sponsorship that made it possible.

Already a member?

Login to keep reading.

Email me a login link